- Home
- EXEL vs NLY Comparison
EXEL vs NLY Comparison
Compare EXEL & NLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | NLY |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | United States | United States |
| Employees | N/A | 212 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 16.3B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXEL | NLY |
|---|---|---|
| Price | $55.65 | $22.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 11 |
| Target Price | ★ $46.50 | $23.82 |
| AVG Volume (30 Days) | 2.5M | ★ 8.0M |
| Earning Date | 05-05-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 12.42% |
| EPS Growth | ★ 57.95 | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $452,477,000.00 | N/A |
| Revenue This Year | $13.61 | $188.83 |
| Revenue Next Year | $13.13 | $2.40 |
| P/E Ratio | $69.59 | ★ $7.88 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.76 | $20.00 |
| 52 Week High | $57.57 | $24.52 |
Technical Indicators
Market Signals| Indicator | EXEL | NLY |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 44.89 |
| Support Level | $40.53 | $22.18 |
| Resistance Level | $57.57 | $23.21 |
| Average True Range (ATR) | 1.32 | 0.42 |
| MACD | -0.33 | -0.09 |
| Stochastic Oscillator | 2.45 | 12.71 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About NLY Annaly Capital Management Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are: the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.